Background: The well-known typical fusion gene BCR/ABL can be observed in connection with a complex translocation event in only 2-10% of cases with chronic myeloid leukemia (CML). As currently most CML cases are treated with Imatinib, variant rearrangements have in general no specific prognostic significance, though the emergence of therapy resistance remains to be studied.
Introduction
Chronic myeloid leukemia (CML), a clonal myeloproliferative disease is known to develop from a pluripotent bone-marrow stem cell following the typical BCR and ABL somatic gene rearrangement. In 90-95% of cases with CML, the BCR/ABL fusion gene is the result of reciprocal translocation between chromosomes 9 and 22 and is cytogenetically observable as a small derivative chromosome 22 which is known as Philadelphia (Ph1) chromosome [1, 2] .
In a Ph-positive CML expression of the BCR/ABL chimeric protein p210 with an increased tyrosine kinase activity is essential for multiple signaling pathways to confer the leukemia phenotype [3] . Imatinib mesylate (Glivec, formerly STI571) was designed specifically to inhibit the tyrosine kinase activity of the bcr/abl protein and other tyrosine kinases such as c-abl, c-kit and platelet-derived growth factor receptor. By binding to an active site of the tyrosine kinase, Imatinib mesylate switches off downstream signaling, cells stop proliferating and apoptosis ensues [4] . Many studies have shown a high efficiency of Imatinib therapy to achieve a complete or major cytogenetic response, i.e. 0-34% Ph-positive cells. This positive effect may be achieved in cases with simple t(9;22), and complex translocations resulting in a BCR/ABL fusion gene, as well as in cases with cytogenetic clonal evolution [5, 6] .
Complex chromosomal rearrangements involving one or more additional chromosomes were described in >600 cases with CML [7] . By conventional cytogenetic analysis, two variant subgroups have traditionally been recognized: complex, t(9;22;V), where V represents a third translocation partner chromosome and simple, t(9;V) or t(22;V) [8] . Only in a few cases is a chromosomal fragment from the third chromosome translocated to the der(22)t(9;22), producing a 'masked Ph' [9] . In most Ph-variant cases the segment 22q11->qter is moved to a third chromosome, while a part of the third chromosome is located on 9q34. Deletions on the derivative chromosome 9 were found to occur with a much higher frequency in patients with variant Ph translocations (45%) than in those with classic Ph (17%) [10] .
Herein we report on a CML cases with new complex aberrations with five chromosomal breakpoints, nonetheless successfully treatable by Imatinib.
Case report
The 45 year old female patient presented initially with a whole blood cell count (WBC) of 43.500/l, splenomegaly and severe loss of weight. Chromosome analysis using banding cytogenetics only revealed a karyotype in concordance with the clinical diagnosis of a CML in chronic phase. She was treated with Hydroxyurea (1000 mg daily dose).
Four years and four months later her WBC was 17.61 × 10 9 /l, i.e. 71.6% neutrophils, 18.9% lymphocytes, 3.1% eosinophiles, 5.1% monocytes, 0.2% basophiles. Platelets count was 650 × 10 9 /l and hemoglobin 12.1 g/dl. She was treated with Imatinib (400 mg daily dose) for overall 10 months. Then her WBC was 27.70 × 10 9 /liter, i.e. 70.2% neutrophils, 16.5% lymphocytes, 5.7% eosinophiles, 6.6% monocytes and 0.1% basophiles. Platelets count was 793 × 10 9 /l and hemoglobin 12.7 g/dl. Serum lactate dehydrogenase (LDH) was 515 U/l (normal up to 480 U/ l), and serum alkaline phosphates was 120 U/l (normal: up to 90 U/l).
Karyotyping was done again at 3 and 10 months after initiation of Imatinib-treatment, respectively, showing additional karyotypic changes. A complex karyotype 46, XX, t(1;4;5;9;22) was determined in GTG-banding (Fig. 1) and further studied by molecular cytogenetics (Fig. 2 and  Fig. 3 ). Dual-color-FISH using a commercially available probe specific for BCR and ABL revealed that the typical Philadelphia-chromosome with BCR/ABL-translocation was present. However, parts of chromosome 22 were present on a der(1) (Fig. 2) . Thus, array-proven high-resolution multicolor banding (aMCB, Fig. 3 ), using probes for the corresponding chromosomes involved according to GTG-banding, was done [11] . The following result was obtained: 46, XX, t,(1;4;5;9;22)(q42;p14;q31;q34;q11.2). Thus, it is most likely that the complexity of the karyotype was missed initially due to low chromosomal resolution.
Discussion
According to the literature, in 2-10% CML cases the fusion gene BCR/ABL is a result of a complex translocation. At GTG-banding revealed a complex karyotype involving three further chromosomes besides chromosomes 9 and 22 Figure 1 GTG-banding revealed a complex karyotype involving three further chromosomes besides chromosomes 9 and 22. All derivative chromosomes are marker by arrowheads. present it appears that variant translocations can affect any chromosome. However, it has been suggested that distribution of the break-points is non-random with the chromosomal bands most susceptible to breakage being: 1p36, 3p21, 5q31, 6p21, 9q22, 10q22, 11q13, 12p13, 17p13, 17q21, 17q25, 19q13, 21q22, 22q12 and 22q13 [7] . In our study we found one out of the three breakpoints to be member of this list, i.e. 5q31. However, the fusion gene remained on chromosome 22.
Two possible mechanisms for variant translocation formation were suggested. The first is a single-event rearrangement via the simultaneous breakage of several chromosomes followed by mismatched joining [12] . Nacheva et al proposed a classical Ph translocation followed by a further translocation event between chromosomes 9 and 22 plus a third chromosome [13] . The mechanism of the formation of a variant Ph translocation may have prognostic importance in that a two-event mechanism represents clonal evolution, whereas a variant translocation occurring via a single genomic rearrangement may confer a similar prognosis to the classical Ph translocation; i.e. clonal evolution has a worse prognosis [14] . According to that, we suggest that the reported patient developed the rearrangement in one initial step and thus, also had such a good response to treatment.
Materials and methods
Banding cytogenetics using GTG-banding was done according to standard procedures [15] ; 20 metaphases derived from unstimulated bone marrow of the patient were analyzed, each.
Fluorescence in situ hybridization (FISH) using commercially available probes for BCR and ABL (Abbott/Vysis) were applied according to manufacturers instructions. High resolution array-proven multicolor-banding (aMCB) based on microdissection derived region-specific libraries for chromosome 1, 4, 5, 9 and 22 was done as described before; method and MCB probe sets are specified [11, 16] . 20 metaphase spreads were analyzed, each using a fluorescence microscope (AxioImager.Z1 mot, Zeiss) equipped with appropriate filter sets to discriminate between a maximum of five fluorochromes and the counterstain DAPI (Diaminophenylindol). Image capturing and processing were carried out using an Isis mFISH imaging system (MetaSystems, Altlussheim, Germany) for the evaluation MCB.
